Medicine
Lynparza 100 mg tablet
Lynparza 100 mg tablet is a prescription medicine containing Olaparib for oral use, marketed by AstraZeneca Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20ºC to 25ºC (68ºF to 77ºF), excursions permitted to 15ºC to 30ºC…
Key facts
- Active ingredient (INN)
- Olaparib
- Brand
- Lynparza
- Strength
- 100 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 120 tablets, 60 tablets and 1 more
- Marketing authorisation holder
- AstraZeneca Pharmaceuticals
- Manufacturer
- AstraZeneca Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20ºC to 25ºC (68ºF to 77ºF), excursions permitted to 15ºC to 30ºC (59ºF to 86ºF). Store in original bottle to protect from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XK01 Olaparib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 17 August 2017
- Identifiers
- RxCUI 1942482, 1942485, 1942487 +1DailyMed set ID 741ff3e3-dc1a-45a6-84e5-2481b27131aaNDC 0310-0668, 0310-0569Application NDA208558
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 120 tablet, film coated in 1 bottle | 0310-0569-12 | AstraZeneca Pharmaceuticals | 18 February 2025 |
| 60 tablet, film coated in 1 bottle, plastic | 0310-0569-60 | AstraZeneca Pharmaceuticals | 13 February 2025 |
| 120 tablet, film coated in 1 bottle | 0310-0668-12 | AstraZeneca Pharmaceuticals | 17 August 2017 |
| 60 tablet, film coated in 1 bottle | 0310-0668-60 | AstraZeneca Pharmaceuticals | 17 August 2017 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Olaparib
Clinical summary
Olaparib is a Poly(ADP-Ribose) polymerase inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, among other approved uses. MedsAcross supplies Olaparib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about OlaparibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Lynparza prescribing information (AstraZeneca Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Lynparza: European public assessment report (EPAR) · European Medicines Agency
Need Lynparza 100 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.